[
    [
        {
            "time": "",
            "original_text": "贵州百灵布局利拉鲁肽，完善糖尿病治疗产业链",
            "features": {
                "keywords": [
                    "贵州百灵",
                    "利拉鲁肽",
                    "糖尿病",
                    "产业链"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贵州百灵布局利拉鲁肽，完善糖尿病治疗产业链",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "浙江省药品交易平台第四季度药品配送率低于60%配送企业",
            "features": {
                "keywords": [
                    "浙江省",
                    "药品交易平台",
                    "配送率",
                    "60%"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "浙江省药品交易平台第四季度药品配送率低于60%配送企业",
                "Correlation": 5,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "[看好评级]医药生物行业2017年年报业绩前瞻：稳健增长 分化明显 重点关注意优质成长与稳健价值",
            "features": {
                "keywords": [
                    "医药生物",
                    "2017年",
                    "年报",
                    "业绩",
                    "稳健增长",
                    "分化明显",
                    "优质成长",
                    "稳健价值"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "[看好评级]医药生物行业2017年年报业绩前瞻：稳健增长 分化明显 重点关注意优质成长与稳健价值",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 5
            }
        }
    ]
]